Arteriocyte is now a part of Isto Biologics.

News + Views


ISTO Technologies to Present at Upcoming Conferences

Mar 5, 2014

March 5, 2014 (St. Louis, MO) – ISTO Technologies, Inc., a privately held regenerative medicine company, announced today announced that Mitchell Seyedin, Ph.D., the Company’s Executive Chairman, will present at the following upcoming investor conferences:

The 9th Annual Canaccord Musculoskeletal Conference
The Sheraton New Orleans Hotel in New Orleans
Presentation: Tuesday, March 11, 2014 at 2:30 p.m. Central Standard Time

The 2nd Annual 2014 Regen Med Investor Day
The Metropolitan Club in New York City
Presentation: Wednesday, March 26, 2014 at 2:15 p.m. Eastern Standard Time

About ISTO Technologies, Inc.
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications.  ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone.  The Company’s proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue.   In addition to cell-based cartilage products in clinical development, ISTO manufactures and markets InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 28,000 surgeries at U.S. hospitals to date.  For additional information on ISTO, please visit our website at

To top